The possibility of eliminating axillary dissection in breast cancer patients using neoadjuvant treatment
Authors:
O. Coufal
Authors‘ workplace:
Klinika operační onkologie, Masarykův onkologický ústav Brno, primář. MUDr. V. Chrenko, CSc.
Published in:
Rozhl. Chir., 2016, roč. 95, č. 11, s. 381-385.
Category:
Review
Overview
Introduction:
Neoadjuvant systemic treatment in breast cancer was initially utilized for patients with locally advanced tumors to achieve resectability. Later on it moved to earlier cancer stages, thus allowing more breast conservations. Current explorations seek to find out whether its effect on axillary metastases could eliminate axillary dissection in treatment responders. Three large prospective trials have studied the accuracy of sentinel lymph node biopsy (SLNB) after clinical regression of nodal metastases in the axilla.
Methods:
As shown by the results, false negativity of SLNB exceeds 10%, which is considered as unacceptably high. The false negativity can be reduced by using the dual tracer technique and/or by removing three nodes at the minimum. An even more promising approach consists in marking the initially metastatic node to ensure its surgical removal along with the regular sentinel nodes. This procedure has been described as “TAD“ (Targeted Axillary Dissection), and extirpation of the marked node is now recommended in NCCN guidelines. However, the appropriate surgical procedure to be used to stage the axilla after clinical regression of nodal metastases still remains a matter of debate. Above all, safety of the conservative approach with respect to local regional control and overall survival is yet unknown.
Results:
Longer follow-up is needed to assess this issue. Despite that, the use of neoadjuvant systemic treatment to reduce axillary dissections seems promising from the current perspective.
Key words:
breast cancer – neoadjuvant treatment – sentinel lymph node biopsy – axillary dissection – false negativity
Sources
1. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483–93.
2. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778–85. Erratum in: J Clin Oncol 2008;26:2793.
3. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599−609.
4. Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010;102:111–8.
5. Krag D, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010;11:927–33.
6. Xing Y, Foy M, Cox DD, et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539–46.
7. Kelly AM, Dwamena B, Cronin P, et al. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol 2009;16:551–63.
8. Boughey JC1, Suman VJ, Mittendorf EA, et al. Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013;310:1455−61.
9. Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicenter cohort study. Lancet Oncol 2013;14:609–18.
10. Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 2014;33:258–64.
11. Zapletal O, Coufal O, Selingerová I, et al. Počet odebíraných axilárních sentinelových uzlin a jeho vliv na diagnostickou přesnost sentinelové biopsie u karcinomu prsu. Rozhl Chir 2013;92:21−6.
12. Caudle AS, Yang WT, Mittendorf EA, et al. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg 2015;150:137–43.
13. Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg 2015;261:378–82.
14. Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 2016;34:1072–8.
15. Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy. Ann Surg 2016;263:802–7.
16. Diego EJ, McAuliffe PF, Soran A, et al. Axillary staging after neoadjuvant chemotherapy for breast cancer: A pilot study combining sentinel lymph node biopsy with radioactive seed localization of pre-treatment positive axillary lymph nodes. Ann Surg Oncol 2016;23:1549−53.
17. NCCN Guidelines Version 2.2016 Invasive Breast Cancer (BINV-11, BINV-13). Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf; cited 2016 Sep 15.
18. Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol 2016;23:3467−74.
19. Choy N, Lipson J, Porter C, et al. Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients. Ann Surg Oncol 2015;22:377−82.
20. Bazan JG, White JR. The role of postmastectomy radiation therapy in patients with breast cancer responding to neoadjuvant chemotherapy. Semin Radiat Oncol 2016;26:51−8.
21. Galimberti V, Ribeiro Fontana SK, Maisonneuve P, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol 2016;42:361−8.
22. van la Parra RF, Kuerer HM. Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Res 2016;18:28.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2016 Issue 11
Most read in this issue
- An uncommon case of purulent mesenteric lymphadenitis
- Rare malignant tumors of the appendix: surgical treatment of liver metastases − case reports
- Total glenoid fractures
- Transplantation of allogeneic bone graft in the therapy of massive post-sternotomy defects – 6 years of experience with the method